Potassium-Removing Drug Effective in Dialysis Patients Potassium-Removing Drug Effective in Dialysis Patients
Sodium zirconium cyclosilicate effectively treats hyperkalemia in patients receiving hemodialysis for end-stage kidney disease, and no new safety concerns were observed in the phase 3 DIALIZE study.Medscape Medical News (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - June 21, 2019 Category: Transplant Surgery Tags: Nephrology News Source Type: news
Pharmacy Tests Turn Up Another Cancer-Causing Compound In Heart Drugs
(CNN) — Tests by an online pharmacy turned up another cancer-causing compound in heart medications, and these drugs haven’t been recalled.
Drugs containing valsaratan, losartan and irbesartan made by a variety of companies in a variety of countries have been taken off pharmacy shelves since July, when tests turned up chemicals in them that are considered carcinogens. The recalls of these angiotensin II receptor blockers or ARBs continue to expand. The US Food and Drug Administration keeps a regularly updated list of the drugs that have been recalled.
In this case, it’s not a recall. Instead, Valisure, an ...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - June 19, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News CNN Valsartan Source Type: news
Teva Pharmaceuticals Expands Patient-Level Losartan Recall Teva Pharmaceuticals Expands Patient-Level Losartan Recall
The new recall of six lots brings the total to 41 lots of bulk losartan potassium sold to Golden State Medical Supply of California.News Alerts (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 12, 2019 Category: Cardiology Tags: Cardiology News Alert Source Type: news
Teva Pharmaceuticals USA, Inc. Expands Voluntary Nationwide Recall of Losartan Potassium to 50 mg and 100 mg Tablets USP, Sold Exclusively to Golden State Medical Supply, Inc.
This expanded recall includes six (6) lots of bulk losartan potassium USP Tablets (two lots of 50 mg strength and four lots of 100 mg strength) due to the detection of an impurity – N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 12, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
UPDATED: Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP and Losartan Potassium and Hydrochlorothiazide Tablets, USP
Torrent Pharmaceuticals Limited is expanding its voluntary recall from 10 lots of Losartan potassium tablets USP to include 6 lots of Losartan potassium and hydrochlorothiazide tablets, USP, to the consumer level due to the detection of trace amounts of an unexpected impurity. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 5, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
